1887 completed. 1887 Phase 1, 549 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1887 | Completed 1887 |
| Phase 2 | 549 | Completed 549 |
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets Selexipag Film Coated Tablets (T1), Selexipag Film Coated Tablets (T2), Uptravi® (selexipag) film coated tablets - Arterial Hypertension (PAH) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2026-04-08 | 2026-07-09 |
| Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects YN001, Rosuvastatin calcium Tablets - Atherosclerotic Cardiovascular Diseases, Cerebrovascular Diseases | Phase 1 | Completed | Beijing Inno Medicine Co., Ltd. | 24 | 2025-12-08 | 2026-09-23 |
| The Effect of an Oral Nutritional Supplement on the Nutritional and Health Outcomes of the Elderly Oral nutritional supplementation - Hypertension, Hand Grip Strength | Phase 1 | Completed | University of Ghana | 81 | 2025-11-24 | 2026-04-21 |
| Study of BB-025, Alone and After BB-031, in Healthy Volunteers BB-025, BB-031 - Pharmacodynamics, Pharmacokinetics | Phase 1 | Completed | Basking Biosciences, Inc. | 72 | 2025-11-05 | 2026-04-06 |
| Effectiveness of Valsartan Alone vs Combination Therapy in Hypertensive Heart Disease Valsartan + Hydrochlorothiazide - Heart Diseases, Hypertension | Phase 1 | Completed | Shaikh Zayed Hospital, Lahore | 118 | 2025-11-01 | 2026-04-22 |
| A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers. BAY 3389934, Matching Placebo / Diluent - Sepsis Associated Disseminated Intravascular Coagulation (DIC) | Phase 1 | Completed | Bayer | 16 | 2025-09-22 | 2026-06-05 |
| Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers BCD101 Low Dose Liquid Formulation, BCD101 High Dose Liquid Formulation, BCD101 Low + High Dose Liquid Formulation - Essential Hypertension | Phase 1 | Completed | Bichedam Co., Ltd. | 57 | 2025-09-22 | 2026-09-29 |
| Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers Vicagrel Capsules, Clopidogrel Tablets - Acute Coronary Syndrome | Phase 1 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 18 | 2025-08-05 | 2025-09-09 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B Co-administration of AD-227A and AD-227B, Administration of AD-227 - Primary Hypertension | Phase 1 | Completed | Addpharma Inc. | 70 | 2025-07-12 | 2025-12-01 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers BR1018, BR1018A, BR1018B - Essential Hypertension, Primary Hypercholesterolemia | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 60 | 2025-05-07 | 2025-09-12 |
| A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity AZD4144, Placebo - Healthy Participants | Phase 1 | Completed | AstraZeneca | 28 | 2025-04-22 | 2025-10-07 |
| The First-in-Human Study of GW906 Injection GW906 injection, Placebo - Hypertension | Phase 1 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 40 | 2025-03-29 | 2026-10-20 |
| To Observe Haemodynamic Parameters Including, Heart Rate, Blood Pressure, Respiratory Rate , and Oxygen Saturation, With or Without Giving Reversal Agent on Extubation, in Patients Receiving Single Shot of Atracurium , and to Observe Post Operative Residual Paralysis and Airway Reflexes in PACU. Placebo drug ( normal saline ), neostigmine (reversal agent) - Tachycardia, Hypertension | Phase 1 / Phase 2 | Completed | Ziauddin University | 100 | 2025-03-12 | 2025-07-31 |
| A Phase 1 Study of Y-3 in US Healthy Volunteers. Y-3 for injection, Placebo - Safety, Tolerability | Phase 1 | Completed | Neurodawn Pharmaceutical Co., Ltd. | 20 | 2025-02-04 | 2025-12-18 |
| A Study of Atorvo+™ in Healthy Adult Participants Atorvo+™ (Arm1), Atorvo+™ +CBD (Arm 2), Atorvo+™ +CBD (Arm 3) - Coronary Heart Disease, Dyslipidemias | Phase 1 | Completed | Indication Bioscience LLC | 24 | 2025-01-28 | 2025-12-19 |
| A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction SGC001, Placebo - Anterior Myocardial Infarction | Phase 1 | Completed | Beijing Sungen Biomedical Technology Co., Ltd | 38 | 2025-01-20 | 2026-01-12 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions BR1015, BR1015-2, BR1015-3 - Essential Hypertension | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 49 | 2025-01-09 | 2025-04-09 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions BR1015, BR1015-1, BR1015-2 - Essential Hypertension | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 48 | 2025-01-05 | 2025-04-09 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions BR1015, BR1015-2, BR1015-3 - Essential Hypertension | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 60 | 2025-01-04 | 2025-04-09 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions BR1015, BR1015-1, BR1015-2 - Essential Hypertension | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 58 | 2025-01-03 | 2025-04-09 |
Showing 20 of 1887. Sign in to see all of them.
Multiple Myeloma (550) · Hypertension (263) · Stroke (172) · Lymphoma, Non-Hodgkin (165) · Leukemia, Lymphocytic, Chronic, B-Cell (157) · Lymphoma, Follicular (142) · Lymphoma, Mantle-Cell (137) · Waldenstrom Macroglobulinemia (130) · Lymphoma, B-Cell, Marginal Zone (129) · Lymphoma, Large B-Cell, Diffuse (123) · Hodgkin Disease (122) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (122) · Lymphoma (116) · Burkitt Lymphoma (105) · Neoplasms, Plasma Cell (104)
Cardiovascular Diseases (1838) · Immune System Diseases (692) · Hemic and Lymphatic Diseases (681) · Hematologic Diseases (662) · Hemorrhagic Disorders (654) · Hemostatic Disorders (642) · Neoplasms by Histologic Type (640) · Blood Protein Disorders (634) · Immunoproliferative Disorders (631) · Lymphoproliferative Disorders (628) · Paraproteinemias (626) · Neoplasms (619) · Pathological Conditions, Signs and Symptoms (556) · Neoplasms, Plasma Cell (530)
Dexamethasone (126) · Bortezomib (76) · Lenalidomide (75) · Cyclophosphamide (61) · Calcium Dobesilate (51) · Melphalan (44) · carfilzomib (37) · fludarabine phosphate (33) · pomalidomide (32) · Rituximab (30) · Peripheral Blood Stem Cell Transplantation (29) · Amlodipine (28) · Filgrastim (27) · fimasartan (26) · fludarabine (21)
National Cancer Institute (NCI) (50) · GlaxoSmithKline (47) · Chong Kun Dang Pharmaceutical (45) · Boryung Pharmaceutical Co., Ltd (41) · Mayo Clinic (36) · Merck Sharp & Dohme LLC (32) · Bristol-Myers Squibb (26) · Bayer (23) · Celgene (22) · AstraZeneca (19) · Novartis Pharmaceuticals (19) · National Heart, Lung, and Blood Institute (NHLBI) (18) · Amgen (17) · Memorial Sloan Kettering Cancer Center (17) · Fred Hutchinson Cancer Center (16)
United States (1071) · South Korea (143) · Germany (100) · United Kingdom (99) · Canada (82) · China (75) · Australia (68) · France (65) · Spain (63) · Italy (51) · Japan (45) · Netherlands (43) · Denmark (24) · Israel (24) · Belgium (23)
PMID 37022569, PMID 24524452, PMID 28803351, PMID 32499241, PMID 11927799, PMID 12119802, PMID 15738343, PMID 18536865, PMID 19238148, PMID 22163120, PMID 22440499, PMID 24475026, PMID 24916507, PMID 26370838, PMID 26589907, PMID 26752061, PMID 26943915, PMID 27561272, PMID 33011075, PMID 33027067, PMID 33175411, PMID 33653620, PMID 33980831, PMID 34174279, PMID 34398557, PMID 35802393, PMID 39545461, PMID 40000533, PMID 40826257, PMID 42287565, PMID 42573020, PMID 10392863, PMID 10492412, PMID 10552943, PMID 10564685, PMID 10662747, PMID 10764422, PMID 10777236, PMID 10793602, PMID 10805617, PMID 10851208, PMID 11018445, PMID 11208675, PMID 11581152, PMID 11686669, PMID 11904109, PMID 12171484, PMID 12270850, PMID 12352030, PMID 12473574
2018 (14), 2015 (13), P30CA015083 (13), 2019 (10), 2009 (8), 2016 (8), 2014 (7), 2017 (7), P30CA006973 (7), P30CA016058 (7), U01CA076576 (7), 2008 (6), P30CA015704 (6), P30CA016672 (5), P30CA022453 (5)